Bone marrow failure (BMF) is a disease that results from the bone marrow’s inability to produce adequate blood cells. These include red blood cells, responsible for carrying oxygen; white blood cells, crucial for the immune system; and platelets, which assist in clotting. When the bone marrow does not function properly, the body is at risk of developing a range of problems, including anemia, infections, and bleeding.
Epidemiology
The incidence of bone marrow failure due to hypoplastic or aplastic anemia is relatively low in the United States and Europe, occurring at a rate of 2-6 cases per million people. In comparison, bone marrow failure due to acute myelogenous leukemia and multiple myeloma has a higher incidence, at 27-35 cases per million people.
Anatomy
Pathophysiology
Impaired Hematopoiesis: Hematopoiesis is the process by which blood cells are formed in the bone marrow. Bone marrow failure affects hematopoiesis, causing the production of fewer numbers of one or more types of blood cells. This may be due to damage to the stem cells (which produce all types of blood cells) or dysfunction of the marrow’s microenvironment, which supports hematopoiesis.
HSC Dysfunction or Depletion: Hematopoietic stem cells (HSCs) reside in the bone marrow, from which all blood cell types are derived. Destruction or depletion of these stem cells compromises the marrow’s ability to produce sufficient blood cells. Genetic defects such as those occurring in Fanconi anemia, dyskeratosis congenita, or aplastic anemia can cause HSC dysfunction.
Bone Marrow Infiltration: Some diseases or cancers for example, leukemia, lymphoma, or metastasis can invade the bone marrow, pushing out the normal hematopoietic cells and preventing the normal production of blood cells. This results in a loss of the ability of the marrow to produce normal blood cells.
Autoimmune Destruction of Hematopoietic Cells: In some cases, bone marrow failure is due to an autoimmune condition. The immune system mistakenly identifies and destroys hematopoietic stem cells or progenitor cells. This is seen in autoimmune aplastic anemia, where T-cells attack the bone marrow cells, impairing blood cell production.
Etiology
Inherited Disorders: Genetic disorders such as Fanconi anemia, dyskeratosis congenita, and Diamond-Blackfan anemia.
Acquired Disorders: Conditions like aplastic anemia, myelodysplastic syndromes (MDS), and leukemia.
Autoimmune Diseases: Systemic lupus erythematosus (SLE) or rheumatoid arthritis can lead to bone marrow failure.
Infections: Viral infections like Epstein-Barr virus and hepatitis can cause BMF.
Chemotherapy or Radiation Therapy: These treatments damage the bone marrow.
Toxins and Drugs: Certain drugs, chemicals, or toxins, such as benzene, can suppress the marrow.
Genetics
Prognostic Factors
Acquired vs. Inherited: Inherited conditions such as dyskeratosis congenita, Fanconi anemia, and Shwachman-Diamond syndrome are often associated with a more complex prognosis due to multisystem involvement and potential progression to malignancy. Acquired conditions (e.g., aplastic anemia, myelodysplastic syndromes) may respond to therapies like immunosuppressive treatment or stem cell transplantation.
Severity of Marrow Failure: The severity of anemia, neutropenia, and thrombocytopenia directly correlates with prognosis. More severe cytopenias are associated with poorer outcomes. Pancytopenia (low counts of all three blood cell types) typically signifies a more severe form of BMF.
Clinical History
Clinical History
Age Group:
Childhood: Bone marrow failure syndromes, including aplastic anemia and inherited conditions like Fanconi anemia, are often diagnosed in children aged 2 to 10.
Adulthood: Acquired bone marrow failure syndromes, including aplastic anemia, may develop in adults, typically during the late 20s to late 50s.
Elderly: Conditions such as myelodysplastic syndromes (MDS) and leukemia are common causes of bone marrow failure in individuals over 60 years old.
Physical Examination
Skin and mucous membranes
Lymphatic system
Cardiovascular system
Respiratory system
Musculoskeletal system
Neurologic examination
Age group
Associated comorbidity
Anemia and related symptoms
Bleeding and bruising
Endocrine dysfunction
Pulmonary issues
Hematologic malignancies
Autoimmune disorders
Associated activity
Acuity of presentation
Bone marrow failure can present acutely with rapidly developing symptoms due to insufficient blood cell production. The severity of symptoms may necessitate immediate medical consultation and treatment. Common symptoms include:
Anemia: Fatigue, paleness, dizziness, and weakness due to low red blood cell counts.
Neutropenia: Increased susceptibility to infections, causing fever and chills.
Thrombocytopenia: Easy bruising, petechiae, and spontaneous bleeding due to low platelet counts.
Possible causes of acute bone marrow failure include aplastic anemia, leukemia, and some familial disorders like dyskeratosis congenita.
Differential Diagnoses
Aplastic anemia
Myelodysplastic syndromes (MDS)
Leukemia
Inherited bone marrow failure syndromes
Paroxysmal nocturnal hemoglobinuria (PNH)
Autoimmune diseases
Nutritional deficiencies
Laboratory Studies
Imaging Studies
Procedures
Histologic Findings
Staging
Treatment Paradigm
Supportive Care:
Transfusions: Red blood cell and platelet transfusions to manage anemia and thrombocytopenia.
Infection Prevention: Broad-spectrum antibiotics, antivirals, and antifungals may be used in cases of neutropenia to prevent and treat infections.
Iron Chelation: Frequent blood transfusions can lead to iron overload, requiring chelation therapy.
Allogeneic Stem Cell Transplantation: A curative option, particularly for patients with severe bone marrow failure or those unresponsive to immunosuppressive therapy.
Matched Donor: Preferably a sibling or unrelated donor with high HLA compatibility.
Cord Blood Transplantation: An option for patients without an ideal stem cell donor.
Androgens:
Danazol: Used primarily for inherited BMF conditions like Diamond-Blackfan anemia, stimulating erythropoiesis and improving red blood cell counts.
Gene Therapy (Emerging Option):
Gene therapy is being explored for specific inherited conditions, such as Fanconi anemia or sickle cell disease, by correcting the genetic defect.
Danazol is a synthetic androgen often used as a treatment option for bone marrow failure in certain contexts, including inherited bone marrow failure syndromes like Dyskeratosis Congenita (DC) or acquired conditions like aplastic anemia. Its use is aimed at stimulating hematopoiesis, the production of blood cells in the bone marrow.
Bone marrow failure (BMF) is a disease that results from the bone marrow’s inability to produce adequate blood cells. These include red blood cells, responsible for carrying oxygen; white blood cells, crucial for the immune system; and platelets, which assist in clotting. When the bone marrow does not function properly, the body is at risk of developing a range of problems, including anemia, infections, and bleeding.
The incidence of bone marrow failure due to hypoplastic or aplastic anemia is relatively low in the United States and Europe, occurring at a rate of 2-6 cases per million people. In comparison, bone marrow failure due to acute myelogenous leukemia and multiple myeloma has a higher incidence, at 27-35 cases per million people.
Impaired Hematopoiesis: Hematopoiesis is the process by which blood cells are formed in the bone marrow. Bone marrow failure affects hematopoiesis, causing the production of fewer numbers of one or more types of blood cells. This may be due to damage to the stem cells (which produce all types of blood cells) or dysfunction of the marrow’s microenvironment, which supports hematopoiesis.
HSC Dysfunction or Depletion: Hematopoietic stem cells (HSCs) reside in the bone marrow, from which all blood cell types are derived. Destruction or depletion of these stem cells compromises the marrow’s ability to produce sufficient blood cells. Genetic defects such as those occurring in Fanconi anemia, dyskeratosis congenita, or aplastic anemia can cause HSC dysfunction.
Bone Marrow Infiltration: Some diseases or cancers for example, leukemia, lymphoma, or metastasis can invade the bone marrow, pushing out the normal hematopoietic cells and preventing the normal production of blood cells. This results in a loss of the ability of the marrow to produce normal blood cells.
Autoimmune Destruction of Hematopoietic Cells: In some cases, bone marrow failure is due to an autoimmune condition. The immune system mistakenly identifies and destroys hematopoietic stem cells or progenitor cells. This is seen in autoimmune aplastic anemia, where T-cells attack the bone marrow cells, impairing blood cell production.
Inherited Disorders: Genetic disorders such as Fanconi anemia, dyskeratosis congenita, and Diamond-Blackfan anemia.
Acquired Disorders: Conditions like aplastic anemia, myelodysplastic syndromes (MDS), and leukemia.
Autoimmune Diseases: Systemic lupus erythematosus (SLE) or rheumatoid arthritis can lead to bone marrow failure.
Infections: Viral infections like Epstein-Barr virus and hepatitis can cause BMF.
Chemotherapy or Radiation Therapy: These treatments damage the bone marrow.
Toxins and Drugs: Certain drugs, chemicals, or toxins, such as benzene, can suppress the marrow.
Acquired vs. Inherited: Inherited conditions such as dyskeratosis congenita, Fanconi anemia, and Shwachman-Diamond syndrome are often associated with a more complex prognosis due to multisystem involvement and potential progression to malignancy. Acquired conditions (e.g., aplastic anemia, myelodysplastic syndromes) may respond to therapies like immunosuppressive treatment or stem cell transplantation.
Severity of Marrow Failure: The severity of anemia, neutropenia, and thrombocytopenia directly correlates with prognosis. More severe cytopenias are associated with poorer outcomes. Pancytopenia (low counts of all three blood cell types) typically signifies a more severe form of BMF.
Clinical History
Age Group:
Childhood: Bone marrow failure syndromes, including aplastic anemia and inherited conditions like Fanconi anemia, are often diagnosed in children aged 2 to 10.
Adulthood: Acquired bone marrow failure syndromes, including aplastic anemia, may develop in adults, typically during the late 20s to late 50s.
Elderly: Conditions such as myelodysplastic syndromes (MDS) and leukemia are common causes of bone marrow failure in individuals over 60 years old.
Skin and mucous membranes
Lymphatic system
Cardiovascular system
Respiratory system
Musculoskeletal system
Neurologic examination
Anemia and related symptoms
Bleeding and bruising
Endocrine dysfunction
Pulmonary issues
Hematologic malignancies
Autoimmune disorders
Bone marrow failure can present acutely with rapidly developing symptoms due to insufficient blood cell production. The severity of symptoms may necessitate immediate medical consultation and treatment. Common symptoms include:
Anemia: Fatigue, paleness, dizziness, and weakness due to low red blood cell counts.
Neutropenia: Increased susceptibility to infections, causing fever and chills.
Thrombocytopenia: Easy bruising, petechiae, and spontaneous bleeding due to low platelet counts.
Possible causes of acute bone marrow failure include aplastic anemia, leukemia, and some familial disorders like dyskeratosis congenita.
Aplastic anemia
Myelodysplastic syndromes (MDS)
Leukemia
Inherited bone marrow failure syndromes
Paroxysmal nocturnal hemoglobinuria (PNH)
Autoimmune diseases
Nutritional deficiencies
Supportive Care:
Transfusions: Red blood cell and platelet transfusions to manage anemia and thrombocytopenia.
Infection Prevention: Broad-spectrum antibiotics, antivirals, and antifungals may be used in cases of neutropenia to prevent and treat infections.
Iron Chelation: Frequent blood transfusions can lead to iron overload, requiring chelation therapy.
Allogeneic Stem Cell Transplantation: A curative option, particularly for patients with severe bone marrow failure or those unresponsive to immunosuppressive therapy.
Matched Donor: Preferably a sibling or unrelated donor with high HLA compatibility.
Cord Blood Transplantation: An option for patients without an ideal stem cell donor.
Androgens:
Danazol: Used primarily for inherited BMF conditions like Diamond-Blackfan anemia, stimulating erythropoiesis and improving red blood cell counts.
Gene Therapy (Emerging Option):
Gene therapy is being explored for specific inherited conditions, such as Fanconi anemia or sickle cell disease, by correcting the genetic defect.
Hematology
Cyclosporine (CsA)
Suppresses T-cell activation and proliferation.
Combined with ATG as first-line therapy for aplastic anemia or other immune-related marrow failures.
Prednisone (or Other Corticosteroids)
Broad immunosuppressive effects.
Sometimes added in combination with other therapies to manage serum sickness or inflammatory reactions.
Hematology
Danzol
Danazol is a synthetic androgen often used as a treatment option for bone marrow failure in certain contexts, including inherited bone marrow failure syndromes like Dyskeratosis Congenita (DC) or acquired conditions like aplastic anemia. Its use is aimed at stimulating hematopoiesis, the production of blood cells in the bone marrow.
Hematology
Hematology
Supportive Care
Blood transfusions for anemia and thrombocytopenia.
Infection prevention and treatment (antibiotics, antifungals, antivirals).
Growth factor support (e.g., erythropoietin, G-CSF for neutropenia).
Definitive Treatment
Hematopoietic Stem Cell Transplantation (HSCT): The only curative option for many inherited or acquired causes.
Immunosuppressive Therapy (IST): Used in conditions like aplastic anemia (e.g., ATG and cyclosporine).
Monitoring and Long-term Care
Regular follow-ups for complications (secondary cancers, organ dysfunction).
Screening for and managing long-term side effects of treatment.
Bone marrow failure (BMF) is a disease that results from the bone marrow’s inability to produce adequate blood cells. These include red blood cells, responsible for carrying oxygen; white blood cells, crucial for the immune system; and platelets, which assist in clotting. When the bone marrow does not function properly, the body is at risk of developing a range of problems, including anemia, infections, and bleeding.
The incidence of bone marrow failure due to hypoplastic or aplastic anemia is relatively low in the United States and Europe, occurring at a rate of 2-6 cases per million people. In comparison, bone marrow failure due to acute myelogenous leukemia and multiple myeloma has a higher incidence, at 27-35 cases per million people.
Impaired Hematopoiesis: Hematopoiesis is the process by which blood cells are formed in the bone marrow. Bone marrow failure affects hematopoiesis, causing the production of fewer numbers of one or more types of blood cells. This may be due to damage to the stem cells (which produce all types of blood cells) or dysfunction of the marrow’s microenvironment, which supports hematopoiesis.
HSC Dysfunction or Depletion: Hematopoietic stem cells (HSCs) reside in the bone marrow, from which all blood cell types are derived. Destruction or depletion of these stem cells compromises the marrow’s ability to produce sufficient blood cells. Genetic defects such as those occurring in Fanconi anemia, dyskeratosis congenita, or aplastic anemia can cause HSC dysfunction.
Bone Marrow Infiltration: Some diseases or cancers for example, leukemia, lymphoma, or metastasis can invade the bone marrow, pushing out the normal hematopoietic cells and preventing the normal production of blood cells. This results in a loss of the ability of the marrow to produce normal blood cells.
Autoimmune Destruction of Hematopoietic Cells: In some cases, bone marrow failure is due to an autoimmune condition. The immune system mistakenly identifies and destroys hematopoietic stem cells or progenitor cells. This is seen in autoimmune aplastic anemia, where T-cells attack the bone marrow cells, impairing blood cell production.
Inherited Disorders: Genetic disorders such as Fanconi anemia, dyskeratosis congenita, and Diamond-Blackfan anemia.
Acquired Disorders: Conditions like aplastic anemia, myelodysplastic syndromes (MDS), and leukemia.
Autoimmune Diseases: Systemic lupus erythematosus (SLE) or rheumatoid arthritis can lead to bone marrow failure.
Infections: Viral infections like Epstein-Barr virus and hepatitis can cause BMF.
Chemotherapy or Radiation Therapy: These treatments damage the bone marrow.
Toxins and Drugs: Certain drugs, chemicals, or toxins, such as benzene, can suppress the marrow.
Acquired vs. Inherited: Inherited conditions such as dyskeratosis congenita, Fanconi anemia, and Shwachman-Diamond syndrome are often associated with a more complex prognosis due to multisystem involvement and potential progression to malignancy. Acquired conditions (e.g., aplastic anemia, myelodysplastic syndromes) may respond to therapies like immunosuppressive treatment or stem cell transplantation.
Severity of Marrow Failure: The severity of anemia, neutropenia, and thrombocytopenia directly correlates with prognosis. More severe cytopenias are associated with poorer outcomes. Pancytopenia (low counts of all three blood cell types) typically signifies a more severe form of BMF.
Clinical History
Age Group:
Childhood: Bone marrow failure syndromes, including aplastic anemia and inherited conditions like Fanconi anemia, are often diagnosed in children aged 2 to 10.
Adulthood: Acquired bone marrow failure syndromes, including aplastic anemia, may develop in adults, typically during the late 20s to late 50s.
Elderly: Conditions such as myelodysplastic syndromes (MDS) and leukemia are common causes of bone marrow failure in individuals over 60 years old.
Skin and mucous membranes
Lymphatic system
Cardiovascular system
Respiratory system
Musculoskeletal system
Neurologic examination
Anemia and related symptoms
Bleeding and bruising
Endocrine dysfunction
Pulmonary issues
Hematologic malignancies
Autoimmune disorders
Bone marrow failure can present acutely with rapidly developing symptoms due to insufficient blood cell production. The severity of symptoms may necessitate immediate medical consultation and treatment. Common symptoms include:
Anemia: Fatigue, paleness, dizziness, and weakness due to low red blood cell counts.
Neutropenia: Increased susceptibility to infections, causing fever and chills.
Thrombocytopenia: Easy bruising, petechiae, and spontaneous bleeding due to low platelet counts.
Possible causes of acute bone marrow failure include aplastic anemia, leukemia, and some familial disorders like dyskeratosis congenita.
Aplastic anemia
Myelodysplastic syndromes (MDS)
Leukemia
Inherited bone marrow failure syndromes
Paroxysmal nocturnal hemoglobinuria (PNH)
Autoimmune diseases
Nutritional deficiencies
Supportive Care:
Transfusions: Red blood cell and platelet transfusions to manage anemia and thrombocytopenia.
Infection Prevention: Broad-spectrum antibiotics, antivirals, and antifungals may be used in cases of neutropenia to prevent and treat infections.
Iron Chelation: Frequent blood transfusions can lead to iron overload, requiring chelation therapy.
Allogeneic Stem Cell Transplantation: A curative option, particularly for patients with severe bone marrow failure or those unresponsive to immunosuppressive therapy.
Matched Donor: Preferably a sibling or unrelated donor with high HLA compatibility.
Cord Blood Transplantation: An option for patients without an ideal stem cell donor.
Androgens:
Danazol: Used primarily for inherited BMF conditions like Diamond-Blackfan anemia, stimulating erythropoiesis and improving red blood cell counts.
Gene Therapy (Emerging Option):
Gene therapy is being explored for specific inherited conditions, such as Fanconi anemia or sickle cell disease, by correcting the genetic defect.
Hematology
Cyclosporine (CsA)
Suppresses T-cell activation and proliferation.
Combined with ATG as first-line therapy for aplastic anemia or other immune-related marrow failures.
Prednisone (or Other Corticosteroids)
Broad immunosuppressive effects.
Sometimes added in combination with other therapies to manage serum sickness or inflammatory reactions.
Hematology
Danzol
Danazol is a synthetic androgen often used as a treatment option for bone marrow failure in certain contexts, including inherited bone marrow failure syndromes like Dyskeratosis Congenita (DC) or acquired conditions like aplastic anemia. Its use is aimed at stimulating hematopoiesis, the production of blood cells in the bone marrow.
Hematology
Hematology
Supportive Care
Blood transfusions for anemia and thrombocytopenia.
Infection prevention and treatment (antibiotics, antifungals, antivirals).
Growth factor support (e.g., erythropoietin, G-CSF for neutropenia).
Definitive Treatment
Hematopoietic Stem Cell Transplantation (HSCT): The only curative option for many inherited or acquired causes.
Immunosuppressive Therapy (IST): Used in conditions like aplastic anemia (e.g., ATG and cyclosporine).
Monitoring and Long-term Care
Regular follow-ups for complications (secondary cancers, organ dysfunction).
Screening for and managing long-term side effects of treatment.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Digital Certificate PDF
On course completion, you will receive a full-sized presentation quality digital certificate.
medtigo Simulation
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
medtigo Points
medtigo points is our unique point redemption system created to award users for interacting on our site. These points can be redeemed for special discounts on the medtigo marketplace as well as towards the membership cost itself.
Community Forum post/reply = 5 points
*Redemption of points can occur only through the medtigo marketplace, courses, or simulation system. Money will not be credited to your bank account. 10 points = $1.
All Your Certificates in One Place
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
